{"title":"An Approach to Minimally Invasive Treatment in Patients With Gastric Cancer Aged Over 80 Years.","authors":"Shota Shimizu, Tomoyuki Matsunaga, Koichiro Kawaguchi, Tomohiro Takahashi, Yukina Yoshida, Yuji Shishido, Kozo Miyatani, Teruhisa Sakamoto, Kazuo Yashima, Hajime Isomoto, Yoshiyuki Fujiwara","doi":"10.21873/anticanres.17699","DOIUrl":null,"url":null,"abstract":"<p><strong>Background/aim: </strong>The number of patients aged ≥80 years with gastric cancer (GC) has recently been increasing. Many have severe comorbidities linked to high mortality after curative surgery. Although minimally invasive surgery is widely performed for GC, elderly patients may benefit from even less invasive, non-standard strategies.</p><p><strong>Patients and methods: </strong>We assessed the treatment outcomes of 122 patients aged ≥80 years who underwent curative gastrectomy at our hospital between 2010-2020.</p><p><strong>Results: </strong>In pStage I, most deaths were from comorbidities, whereas deaths in pStage II/III were both disease-specific and from comorbidities. Multivariate analysis of pStage I variables identified low prognostic nutritional index, open surgery, and American Society of Anesthesiologists physical status classification ≥3 as poor prognostic factors. For pStage II/III, no factors were significantly associated with mortality. Forty-seven out of 69 patients with T1 disease would have been classified as achieving Endoscopic Curability C-2 (eCuraC-2) if endoscopic resection rather than surgery had been performed. The 5-year overall survival rates were similar (58.8% <i>vs.</i> 68.6%, <i>p</i>=0.66) in the 20 patients judged as having eCuraC-2 status after endoscopic resection, with no other additional treatment.</p><p><strong>Conclusion: </strong>Minimally invasive surgery with limited lymph node dissection is preferred for elderly patients with GC with severe comorbidities, including malnutrition, and observation after noncurative endoscopic resection is viable.</p>","PeriodicalId":8072,"journal":{"name":"Anticancer research","volume":"45 8","pages":"3383-3391"},"PeriodicalIF":1.7000,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Anticancer research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21873/anticanres.17699","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background/aim: The number of patients aged ≥80 years with gastric cancer (GC) has recently been increasing. Many have severe comorbidities linked to high mortality after curative surgery. Although minimally invasive surgery is widely performed for GC, elderly patients may benefit from even less invasive, non-standard strategies.
Patients and methods: We assessed the treatment outcomes of 122 patients aged ≥80 years who underwent curative gastrectomy at our hospital between 2010-2020.
Results: In pStage I, most deaths were from comorbidities, whereas deaths in pStage II/III were both disease-specific and from comorbidities. Multivariate analysis of pStage I variables identified low prognostic nutritional index, open surgery, and American Society of Anesthesiologists physical status classification ≥3 as poor prognostic factors. For pStage II/III, no factors were significantly associated with mortality. Forty-seven out of 69 patients with T1 disease would have been classified as achieving Endoscopic Curability C-2 (eCuraC-2) if endoscopic resection rather than surgery had been performed. The 5-year overall survival rates were similar (58.8% vs. 68.6%, p=0.66) in the 20 patients judged as having eCuraC-2 status after endoscopic resection, with no other additional treatment.
Conclusion: Minimally invasive surgery with limited lymph node dissection is preferred for elderly patients with GC with severe comorbidities, including malnutrition, and observation after noncurative endoscopic resection is viable.
期刊介绍:
ANTICANCER RESEARCH is an independent international peer-reviewed journal devoted to the rapid publication of high quality original articles and reviews on all aspects of experimental and clinical oncology. Prompt evaluation of all submitted articles in confidence and rapid publication within 1-2 months of acceptance are guaranteed.
ANTICANCER RESEARCH was established in 1981 and is published monthly (bimonthly until the end of 2008). Each annual volume contains twelve issues and index. Each issue may be divided into three parts (A: Reviews, B: Experimental studies, and C: Clinical and Epidemiological studies).
Special issues, presenting the proceedings of meetings or groups of papers on topics of significant progress, will also be included in each volume. There is no limitation to the number of pages per issue.